LS@W alumnus Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases
Study will examine impact on cognitive function from one of the most advanced disease-modifying drug treatments for…
Lifesciences@Work : We help scientists build their business
Recent Comments